<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.113184</article-id><article-id pub-id-type="publisher-id">ACM-41265</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210300000_31066918.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  早产儿血小板减少症的临床特征及结局分析
  Clinical Characteristics and Outcome Analysis of Premature Infants with Thrombocytopenia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>袁</surname><given-names>芮</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>向红</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郝</surname><given-names>荣真</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>丽娟</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>青岛大学附属医院，山东 青岛</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>03</month><year>2021</year></pub-date><volume>11</volume><issue>03</issue><fpage>1284</fpage><lpage>1293</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：回顾性分析早产儿血小板减少症的临床资料，探讨早产儿血小板减少症的临床特征及转归，分析血小板的输注对其临床结局的影响。方法：选择2017年1月至2018年12月出生的194例血小板减少(血小板 &lt; 150 &#215; 109/L)早产儿为研究对象，依据血小板减少严重程度分为轻度血小板减少组(血小板100 &#215; 109/L~150 &#215; 109/L)、中度血小板减少组(血小板50 &#215; 109/L~99 &#215; 109/L)及重度血小板减少组(血小板小于50 &#215; 109/L)。按照胎龄分为胎龄 &lt; 34周组、胎龄 ≥ 34周组。按照发病日龄分为早发型血小板减少组(发病 &lt; 3天)和晚发型血小板减少组(发病 ≥ 3天)。比较患儿母孕期情况、患儿出生情况、临床特点及转归，分析血小板减少病因及血小板的输注对临床结局的影响。结果：早产儿血小板减少首要病因为围产期因素，约占43.8%；晚发型血小板减少组的败血症(P = 0.000)和NEC (P = 0.033)比例明显高于早发型血小板减少组；NEC在血小板重度减少组所占比例较轻、中度血小板减少组明显增加(P = 0.000)；重度血小板减少组的早产儿容易发生重度出血(P = 0.000)，血小板输注后重度出血仍较高(P = 0.000)。结论：1) 早产儿血小板减少病因以围产期因素多见，可以导致不同程度的血小板减少。2) 败血症、NEC是晚发型血小板减少的重要病因。NEC导致血小板减少的程度一般较重。3) 重度血小板减少的出血情况比较严重，输注血小板后没有减少严重出血。
    Objective: To retrospectively analyze the clinical data of premature infants with thrombocytopenia, explore the clinical characteristics and prognosis of premature infants with thrombocytopenia, and analyze the effect of platelet transfusion on its clinical outcome. Methods: A total of 194 premature infants with thrombocytopenia (thrombocytopenia &lt; 150 &#215; 109/L) born from January 2017 to December 2018 were selected as the study subjects. According to the severity of thrombocytopenia, they were divided into the mild thrombocytopenia group (thrombocytopenia 100 &#215; 109/L~150 &#215; 109/L), the moderate thrombocytopenia group (thrombocytopenia 50 &#215; 109/L~99 &#215; 109/L) and the severe thrombocytopenia group (thrombocytopenia less than 50 &#215; 109/L). According to gestational age, they were divided into the gestational age &lt; 34 weeks group and the gestational age ≥ 34 weeks group. According to the onset age, they were divided into the early onset group (onset &lt; 3 days) and the late onset group (onset ≥ 3 days). The pregnancy, birth, clinical characteristics and outcomes of the mothers of the children were compared, and the causes of thrombocytopenia and the effects of platelet transfusion on clinical outcomes were analyzed. Results: The primary cause of thrombocytopenia in premature infants was perinatal factors, accounting for 43.8%; The proportion of sepsis (P = 0.000) and NEC (P = 0.033) in late onset thrombocytopenia group was significantly higher than that in early onset thrombocytopenia group; The proportion of NEC was higher in the severe thrombocytopenia group (P = 0.00); Premature infants in the severe thrombocytopenia group were prone to severe bleeding (P = 0.000), and severe bleeding was still higher after platelet transfusion (P = 0.000). Conclusion: 1) The causes of thrombocytopenia in premature infants were mostly perinatal factors, which could lead to thrombocytopenia in different degrees. 2) Sepsis and NEC are important causes of late onset thrombocytopenia. NEC often results in severe thrombocytopenia. 3) Severe thrombocytopenia has severe bleeding, and platelet transfusion doesn’t reduce severe bleeding. 
  
 
</p></abstract><kwd-group><kwd>早产儿，血小板减少，出血，血小板输注, Premature Infants</kwd><kwd> Thrombocytopenia</kwd><kwd> Bleed</kwd><kwd> Platelet Transfusion</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>目的：回顾性分析早产儿血小板减少症的临床资料，探讨早产儿血小板减少症的临床特征及转归，分析血小板的输注对其临床结局的影响。方法：选择2017年1月至2018年12月出生的194例血小板减少(血小板 &lt; 150 &#215; 10<sup>9</sup>/L)早产儿为研究对象，依据血小板减少严重程度分为轻度血小板减少组(血小板100 &#215; 10<sup>9</sup>/L~150 &#215; 10<sup>9</sup>/L)、中度血小板减少组(血小板50 &#215; 10<sup>9</sup>/L~99 &#215; 10<sup>9</sup>/L)及重度血小板减少组(血小板小于50 &#215; 10<sup>9</sup>/L)。按照胎龄分为胎龄 &lt; 34周组、胎龄 ≥ 34周组。按照发病日龄分为早发型血小板减少组(发病 &lt; 3天)和晚发型血小板减少组(发病 ≥ 3天)。比较患儿母孕期情况、患儿出生情况、临床特点及转归，分析血小板减少病因及血小板的输注对临床结局的影响。结果：早产儿血小板减少首要病因为围产期因素，约占43.8%；晚发型血小板减少组的败血症(P = 0.000)和NEC (P = 0.033)比例明显高于早发型血小板减少组；NEC在血小板重度减少组所占比例较轻、中度血小板减少组明显增加(P = 0.000)；重度血小板减少组的早产儿容易发生重度出血(P = 0.000)，血小板输注后重度出血仍较高(P = 0.000)。结论：1) 早产儿血小板减少病因以围产期因素多见，可以导致不同程度的血小板减少。2) 败血症、NEC是晚发型血小板减少的重要病因。NEC导致血小板减少的程度一般较重。3) 重度血小板减少的出血情况比较严重，输注血小板后没有减少严重出血。</p></sec><sec id="s2"><title>关键词</title><p>早产儿，血小板减少，出血，血小板输注</p></sec><sec id="s3"><title>Clinical Characteristics and Outcome Analysis of Premature Infants with Thrombocytopenia</title><p>Rui Yuan, Xianghong Li<sup>*</sup>, Rongzhen Hao, Lijuan Yang</p><p>The Affiliated Hospital of Qingdao University, Qingdao Shandong</p><p><img src="//html.hanspub.org/file/67-1572074x5_hanspub.png" /></p><p>Received: Feb. 23<sup>rd</sup>, 2021; accepted: Mar. 11<sup>th</sup>, 2021; published: Mar. 29<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/67-1572074x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Objective: To retrospectively analyze the clinical data of premature infants with thrombocytopenia, explore the clinical characteristics and prognosis of premature infants with thrombocytopenia, and analyze the effect of platelet transfusion on its clinical outcome. Methods: A total of 194 premature infants with thrombocytopenia (thrombocytopenia &lt; 150 &#215; 10<sup>9</sup>/L) born from January 2017 to December 2018 were selected as the study subjects. According to the severity of thrombocytopenia, they were divided into the mild thrombocytopenia group (thrombocytopenia 100 &#215; 10<sup>9</sup>/L~150 &#215; 10<sup>9</sup>/L), the moderate thrombocytopenia group (thrombocytopenia 50 &#215; 10<sup>9</sup>/L~99 &#215; 10<sup>9</sup>/L) and the severe thrombocytopenia group (thrombocytopenia less than 50 &#215; 10<sup>9</sup>/L). According to gestational age, they were divided into the gestational age &lt; 34 weeks group and the gestational age ≥ 34 weeks group. According to the onset age, they were divided into the early onset group (onset &lt; 3 days) and the late onset group (onset ≥ 3 days). The pregnancy, birth, clinical characteristics and outcomes of the mothers of the children were compared, and the causes of thrombocytopenia and the effects of platelet transfusion on clinical outcomes were analyzed. Results: The primary cause of thrombocytopenia in premature infants was perinatal factors, accounting for 43.8%; The proportion of sepsis (P = 0.000) and NEC (P = 0.033) in late onset thrombocytopenia group was significantly higher than that in early onset thrombocytopenia group; The proportion of NEC was higher in the severe thrombocytopenia group (P = 0.00); Premature infants in the severe thrombocytopenia group were prone to severe bleeding (P = 0.000), and severe bleeding was still higher after platelet transfusion (P = 0.000). Conclusion: 1) The causes of thrombocytopenia in premature infants were mostly perinatal factors, which could lead to thrombocytopenia in different degrees. 2) Sepsis and NEC are important causes of late onset thrombocytopenia. NEC often results in severe thrombocytopenia. 3) Severe thrombocytopenia has severe bleeding, and platelet transfusion doesn’t reduce severe bleeding.</p><p>Keywords:Premature Infants, Thrombocytopenia, Bleed, Platelet Transfusion</p><disp-formula id="hanspub.41265-formula35"><graphic xlink:href="//html.hanspub.org/file/67-1572074x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/67-1572074x8_hanspub.png" /> <img src="//html.hanspub.org/file/67-1572074x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>近年来，随着围产医学及新生儿救治水平的不断提高，早产儿和低出生体重儿存活率呈现逐渐增加的态势，但一些影响远期预后的因素，比如颅内出血等发病率仍然居高不下，严重影响早产儿的生存质量。血小板减少是新生儿常见的血液系统疾病，早产儿中发病率更高 [<xref ref-type="bibr" rid="hanspub.41265-ref1">1</xref>]，出生体重小于1000 g早产儿中，血小板减少发生率可达75% [<xref ref-type="bibr" rid="hanspub.41265-ref2">2</xref>]，新生儿重症监护室(newborn intensive care unit, NICU)的新生儿血小板减少发生率为22%~35% [<xref ref-type="bibr" rid="hanspub.41265-ref3">3</xref>]，胎龄增加，早产儿外周血中血小板计数会随之增加，随着胎龄减小，发病率逐渐升高 [<xref ref-type="bibr" rid="hanspub.41265-ref4">4</xref>]。因此有必要对早产儿血小板减少病因和临床特点进行全面分析，指导诊疗过程，提高早产儿远期预后。</p><p>健康足月新生儿出生时血小板平均为380 &#177; 69 &#215; 10<sup>9</sup>/L [<xref ref-type="bibr" rid="hanspub.41265-ref5">5</xref>]，早产儿由于母亲因素或自身因素等原因是血小板减少的最常见高危人群，其病因、临床特征及转归与足月儿显著不同。国内目前针对早产儿血小板减少症的临床研究少有报道。本文通过回顾早产儿血小板减少的临床资料，分析其临床特点、病因及结局，并探讨早产儿血小板输注与结局相关性，为临床规范诊治提供依据。</p></sec><sec id="s6"><title>2. 对象和方法</title><sec id="s6_1"><title>2.1. 研究对象与分组</title><p>选择2017年1月至2018年12月年间，我院收治的符合《实用新生儿学》第4版血小板减少诊断标准的早产儿胎龄(&lt;37周)为研究对象。采用三种分组方法依次分析。分组1：按照血小板减少严重程度分为轻度(100~150 &#215; 10<sup>9</sup>/L)、中度(50~99 &#215; 10<sup>9</sup>/L)及重度(&lt;50 &#215; 10<sup>9</sup>/L)血小板减少组 [<xref ref-type="bibr" rid="hanspub.41265-ref6">6</xref>]；分组2：按照胎龄分为胎龄 &lt; 34周组、胎龄 ≥ 34周组；分组3：按照发病日龄分为早发型血小板减少组(发病 &lt; 3天)和晚发型血小板减少组(发病 ≥ 3天)。排除生后因血标本不合格，检验报告未发出，或报告发出后立即复查血小板升高至正常的早产儿。</p></sec><sec id="s6_2"><title>2.2. 方法</title><p>此次研究为回顾性分析，本着知情同意的原则，已告知患儿家属，并签署《知情同意书》。将患儿母孕期情况、出生情况、临床特征、实验室检查、治疗及转归等进行登记，分析血小板减少的病因构成、临床特点及转归；具体收集的资料如下：</p><p>1) 患儿的出生情况和临床合并症：性别、分娩方式、胎龄、出生体重、小于胎龄儿、呼吸衰竭或新生儿呼吸窘迫综合征(neonatal respiratory distress syndrome, NRDS)、宫内窘迫、出血情况、败血症、新生儿坏死性小肠结肠炎(necrotizing enterocolitis of newborn, NEC)、支气管肺发育不良(bronchopulmonary dysplasia, BPD)、DIC、染色体异常、早产儿贫血等。《实用新生儿学》第4版将生后3天以内出血的败血症定义为早发败血症。</p><p>2) 母孕期情况：母亲年龄、孕次、产次、妊娠高血压、孕母是否合并血小板减少及免疫系统疾病。</p><p>3) 临床症状(出血情况)：具体出血部位及严重程度。依据《实用新生儿学》第4版将颅内出血、肺出血或危及生命的消化道出血定义为重度出血，其余不危及生命的出血如皮肤出血等定义为轻度出血。</p><p>4) 实验室检查：血小板减少情况(发病日龄、最低值、血小板恢复时间)，凝血功能。</p><p>5) 治疗及转归：输血或血制品(包括血浆、冷沉淀、血小板、人免疫球蛋白)、肺表面活性物质、无创呼吸机、有创呼吸机、死亡或放弃治疗。</p></sec><sec id="s6_3"><title>2.3. 统计学分析</title><p>采用SPSS 25软件对数据统计分析，定性资料采用卡方分析，对于期望计数小于5的，采用Fisher确切分析法。定量资料符合正态分布采用t检验，如不符合正态分布采用秩和检验。</p></sec></sec><sec id="s7"><title>3. 结果</title><sec id="s7_1"><title>3.1. 患儿临床基本情况</title><p>本研究期间共有1485名早产儿在我院新生儿重症监护病房住院，共有194例血小板减少早产儿，发病率13.06% (194/1485)。</p><p>194例血小板早产儿发病日龄最早为生后即出现血小板减少，最晚为生后63天，中位数为2天。早发型血小板减少症组124例，占64%，晚发型血小板减少症组70例，占36%。轻度血小板减少组占65% (125/194)；中度血小板27% (53/194)；重度血小板减少组8% (16/194)。有出血表现者占42.8% (83/194)，轻度出血占79.5% (66/83)，重度出血占20.5% (17/83)。死亡或放弃治疗占10.8% (21/194)。</p></sec><sec id="s7_2"><title>3.2. 病因构成</title><p>早产儿血小板减少病因，如表1所示，按败血症(包括早发败血症、晚发败血症)、NEC、DIC、免疫因素(包括新生儿同族免疫性血小板减少性紫癜、新生儿自身免疫血小板减少性紫癜、孕母血小板减少等)、围产期因素(包括妊高症、窒息、SGA等)、NRDS、染色体异常等进行分类。围产期因素为第一位原因(占43.8%)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Etiological composition of thrombocytopenia in premature infant</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >病因</th><th align="center" valign="middle" >人数(n = 194)</th></tr></thead><tr><td align="center" valign="middle" >NRDS</td><td align="center" valign="middle" >30 (15.5%)</td></tr><tr><td align="center" valign="middle" >围产期因素</td><td align="center" valign="middle" >85 (43.8%)</td></tr><tr><td align="center" valign="middle" >免疫因素</td><td align="center" valign="middle" >15 (7.7%)</td></tr><tr><td align="center" valign="middle" >NEC</td><td align="center" valign="middle" >8 (4.1%)</td></tr><tr><td align="center" valign="middle" >DIC</td><td align="center" valign="middle" >8 (4.1%)</td></tr><tr><td align="center" valign="middle" >染色体异常</td><td align="center" valign="middle" >4 (2.1%)</td></tr><tr><td align="center" valign="middle" >败血症</td><td align="center" valign="middle" >21 (10.8%)</td></tr><tr><td align="center" valign="middle" >其它原因</td><td align="center" valign="middle" >23 (11.8%)</td></tr></tbody></table></table-wrap><p>表1. 早产儿血小板减少的病因构成</p><p>(一) 按胎龄分组分析</p><p>胎龄 &lt; 34周组与胎龄 ≥ 34周组血小板较少的第一位病因均为围产期因素，见表2。胎龄 &lt; 34周组NRDS为第二位病因，较胎龄 ≥ 34周组要高(P = 0.001)。围产因素中SGA及妊高症在胎龄 ≥ 34周组占比明显高于胎龄 &lt; 34周组，P值分别为0.006、0.042。两组间免疫因素、NEC、DIC、染色体异常以及败血症无明显差别。某些患儿同时存在多种围产期因素，将这些因素均作为病因纳入讨论。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Compare the causes of thrombocytopenia in premature infants with gestational age &lt; 34 weeks and gestational age ≥ 34 week</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >&lt;34周(n = 115)</th><th align="center" valign="middle" >≥34周(n = 79)</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >NRDS</td><td align="center" valign="middle" >26 (22.6%)</td><td align="center" valign="middle" >4 (5.1%)</td><td align="center" valign="middle" >11.028</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >围产期因素</td><td align="center" valign="middle" >43 (37.4%)</td><td align="center" valign="middle" >42 (53.2%)</td><td align="center" valign="middle" >4.733</td><td align="center" valign="middle" >0.030</td></tr><tr><td align="center" valign="middle" >SGA</td><td align="center" valign="middle" >8 (7.0%)</td><td align="center" valign="middle" >16 (20.3%)</td><td align="center" valign="middle" >7.637</td><td align="center" valign="middle" >0.006</td></tr><tr><td align="center" valign="middle" >妊高症</td><td align="center" valign="middle" >28 (24.3%)</td><td align="center" valign="middle" >30 (38.0%)</td><td align="center" valign="middle" >4.149</td><td align="center" valign="middle" >0.042</td></tr><tr><td align="center" valign="middle" >宫内窘迫</td><td align="center" valign="middle" >30 (26.1%)</td><td align="center" valign="middle" >15 (19.0%)</td><td align="center" valign="middle" >1.325</td><td align="center" valign="middle" >0.250</td></tr><tr><td align="center" valign="middle" >免疫因素</td><td align="center" valign="middle" >7 (6.1%)</td><td align="center" valign="middle" >8 (10.1%)</td><td align="center" valign="middle" >1.071</td><td align="center" valign="middle" >0.301</td></tr><tr><td align="center" valign="middle" >NEC</td><td align="center" valign="middle" >7 (6.1%)</td><td align="center" valign="middle" >1 (1.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.145</td></tr><tr><td align="center" valign="middle" >DIC</td><td align="center" valign="middle" >4 (3.5%)</td><td align="center" valign="middle" >4 (5.1%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.718</td></tr><tr><td align="center" valign="middle" >染色体异常</td><td align="center" valign="middle" >2 (1.7%)</td><td align="center" valign="middle" >2 (2.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >败血症</td><td align="center" valign="middle" >14 (12.2%)</td><td align="center" valign="middle" >7 (8.9%)</td><td align="center" valign="middle" >0.533</td><td align="center" valign="middle" >0.466</td></tr><tr><td align="center" valign="middle" >早发败血症</td><td align="center" valign="middle" >7 (6.1%)</td><td align="center" valign="middle" >5 (6.7%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >晚发败血症</td><td align="center" valign="middle" >7 (6.1%)</td><td align="center" valign="middle" >2 (2.5%)</td><td align="center" valign="middle" >1.338</td><td align="center" valign="middle" >0.247</td></tr><tr><td align="center" valign="middle" >其他原因</td><td align="center" valign="middle" >12 (10.4%)</td><td align="center" valign="middle" >11 (13.9%)</td><td align="center" valign="middle" >0.546</td><td align="center" valign="middle" >0.460</td></tr></tbody></table></table-wrap><p>表2. 胎龄 &lt; 34周与胎龄 ≥ 34周早产儿血小板减少的病因比较</p><p>(二) 按发病日龄分析</p><p>如表3所示，早发型血小板减少围产期因素为第一位病因，明显高于晚发型血小板减少组(P = 0.001)。晚发型血小板减少组的败血症、NEC比例明显高于早发型血小板减少组。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Compare the causes of thrombocytopenia in premature infants with early onset thrombocytopenia and late onset thrombocytopeni</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >早发型(n = 124)</th><th align="center" valign="middle" >晚发型(n = 70)</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >NRDS</td><td align="center" valign="middle" >15 (12.1%)</td><td align="center" valign="middle" >15 (21.4%)</td><td align="center" valign="middle" >2.980</td><td align="center" valign="middle" >0.084</td></tr><tr><td align="center" valign="middle" >围产期因素</td><td align="center" valign="middle" >65 (52.4%)</td><td align="center" valign="middle" >20 (28.6%)</td><td align="center" valign="middle" >10.337</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >SGA</td><td align="center" valign="middle" >19 (15.3%)</td><td align="center" valign="middle" >5 (7.1%)</td><td align="center" valign="middle" >2.761</td><td align="center" valign="middle" >0.097</td></tr><tr><td align="center" valign="middle" >妊高症</td><td align="center" valign="middle" >43 (34.7%)</td><td align="center" valign="middle" >15 (21.4%)</td><td align="center" valign="middle" >3.747</td><td align="center" valign="middle" >0.053</td></tr><tr><td align="center" valign="middle" >宫内窘迫</td><td align="center" valign="middle" >34 (27.4%)</td><td align="center" valign="middle" >11 (15.7%)</td><td align="center" valign="middle" >3.441</td><td align="center" valign="middle" >0.064</td></tr><tr><td align="center" valign="middle" >免疫因素</td><td align="center" valign="middle" >12 (9.7%)</td><td align="center" valign="middle" >3 (4.3%)</td><td align="center" valign="middle" >1.823</td><td align="center" valign="middle" >0.177</td></tr><tr><td align="center" valign="middle" >NEC</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >8 (11.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >DIC</td><td align="center" valign="middle" >6 (4.8%)</td><td align="center" valign="middle" >2 (2.9%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.713</td></tr><tr><td align="center" valign="middle" >染色体异常</td><td align="center" valign="middle" >3 (2.4%)</td><td align="center" valign="middle" >1 (1.4%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1.000</td></tr><tr><td align="center" valign="middle" >败血症</td><td align="center" valign="middle" >9 (7.3%)</td><td align="center" valign="middle" >12 (17.1%)</td><td align="center" valign="middle" >4.529</td><td align="center" valign="middle" >0.033</td></tr><tr><td align="center" valign="middle" >早发败血症</td><td align="center" valign="middle" >9 (7.3%)</td><td align="center" valign="middle" >3 (4.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.542</td></tr><tr><td align="center" valign="middle" >晚发败血症</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >9 (12.9%)</td><td align="center" valign="middle" >13.930</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >其他原因</td><td align="center" valign="middle" >15 (12.1%)</td><td align="center" valign="middle" >8 (11.4%)</td><td align="center" valign="middle" >0.019</td><td align="center" valign="middle" >0.890</td></tr></tbody></table></table-wrap><p>表3. 早发型、晚发型血小板减少早产儿血小板减少病因比较</p><p>(三) 按严重程度分析</p><p>NEC在血小板重度减少组所占比例较轻、中度血小板减少组明显增加(P = 0.000)其余因素在3组中无明显统计学差异，见表4。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Compare the causes of thrombocytopenia in premature infants with the leve</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >轻度减少(n = 125)</th><th align="center" valign="middle" >中度减少(n = 53)</th><th align="center" valign="middle" >重度减少(n = 16)</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >RDS</td><td align="center" valign="middle" >20 (16.0%)</td><td align="center" valign="middle" >9 (17.0%)</td><td align="center" valign="middle" >1 (6.3%)</td><td align="center" valign="middle" >1.160</td><td align="center" valign="middle" >0.640</td></tr><tr><td align="center" valign="middle" >围产期因素</td><td align="center" valign="middle" >60 (48.0%)</td><td align="center" valign="middle" >19 (35.8%)</td><td align="center" valign="middle" >6 (37.5%)</td><td align="center" valign="middle" >2.515</td><td align="center" valign="middle" >0.284</td></tr><tr><td align="center" valign="middle" >SGA</td><td align="center" valign="middle" >18 (14.4%)</td><td align="center" valign="middle" >4 (7.5%)</td><td align="center" valign="middle" >2 (12.5%)</td><td align="center" valign="middle" >1.613</td><td align="center" valign="middle" >0.449</td></tr><tr><td align="center" valign="middle" >妊高症</td><td align="center" valign="middle" >43 (34.4%)</td><td align="center" valign="middle" >11 (20.8%)</td><td align="center" valign="middle" >4 (25.0%)</td><td align="center" valign="middle" >3.506</td><td align="center" valign="middle" >0.170</td></tr><tr><td align="center" valign="middle" >宫内窘迫</td><td align="center" valign="middle" >29 (23.2%)</td><td align="center" valign="middle" >10 (18.9%)</td><td align="center" valign="middle" >6 (37.5%)</td><td align="center" valign="middle" >2.395</td><td align="center" valign="middle" >0.302</td></tr><tr><td align="center" valign="middle" >免疫因素</td><td align="center" valign="middle" >7 (5.6%)</td><td align="center" valign="middle" >8 (15.1%)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.077</td></tr><tr><td align="center" valign="middle" >NEC</td><td align="center" valign="middle" >1 (0.8%)</td><td align="center" valign="middle" >3 (5.7%)</td><td align="center" valign="middle" >4 (25.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >DIC</td><td align="center" valign="middle" >4 (3.2%)</td><td align="center" valign="middle" >2 (3.8%)</td><td align="center" valign="middle" >2 (12.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.260</td></tr><tr><td align="center" valign="middle" >染色体异常</td><td align="center" valign="middle" >1 (0.8%)</td><td align="center" valign="middle" >3 (5.7%)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.146</td></tr><tr><td align="center" valign="middle" >败血症</td><td align="center" valign="middle" >14 (11.2%)</td><td align="center" valign="middle" >6 (11.3%)</td><td align="center" valign="middle" >1 (6.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.805</td></tr><tr><td align="center" valign="middle" >早发败血症</td><td align="center" valign="middle" >9 (7.2%)</td><td align="center" valign="middle" >3 (5.7%)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.806</td></tr><tr><td align="center" valign="middle" >晚发败血症</td><td align="center" valign="middle" >5 (4.0%)</td><td align="center" valign="middle" >3 (5.7%)</td><td align="center" valign="middle" >1 (6.3%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.851</td></tr><tr><td align="center" valign="middle" >其他原因</td><td align="center" valign="middle" >18 (14.4%)</td><td align="center" valign="middle" >3 (5.7%)</td><td align="center" valign="middle" >2 (12.5%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.213</td></tr></tbody></table></table-wrap><p>表4. 血小板减少轻、中、重度病因比较</p></sec><sec id="s7_3"><title>3.3. 早发型与晚发型血小板减少的临床分析比较</title><p>晚发型血小板减少组的胎龄及出生体重明显低于早发型血小板减少组(P值分别为0.001、0.014)，晚发型血小板减少症组中胎龄 &lt; 34周高于早发型血小板减少症组。晚发型血小板减少组中早产儿贫血的发生率高于早发型血小板减少组(P = 0.000)，但是两组间出血情况(轻度、重度)、血小板减少持续时间、血小板的最低值以及凝血异常等均未见显著差异。预后上，两组之间死亡或放弃治疗未见明显差异，见表5。</p></sec><sec id="s7_4"><title>3.4. 血小板减少严重程度的临床分析比较</title><p>重度血小板减少组有更低的出生体重(P = 0.019)，血小板恢复所需时间长(P = 0.047)，更容易发生凝血异常以及重度出血(P = 0.000)，需要血小板以及其他血制品防治出血。重度血小板减少组患儿呼吸问题较轻、中度血小板减少组患儿严重，需要呼吸机辅助通气的比例也较高。重度血小板减少组往往病情较重，死亡及放弃治疗的比例明显高于另外两组(P = 0.002)，见表6。</p><table-wrap id="table5" ><label><xref ref-type="table" rid="table5">Table 5</xref></label><caption><title> Clinical analysis of early onset thrombocytopenia and late onset thrombocytopeni</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >早发型(n = 124)</th><th align="center" valign="middle" >晚发型(n = 70)</th><th align="center" valign="middle" >Z/X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >胎龄(w)</td><td align="center" valign="middle" >33.64</td><td align="center" valign="middle" >31.785</td><td align="center" valign="middle" >−3.257</td><td align="center" valign="middle" >0.001</td></tr><tr><td align="center" valign="middle" >体重(g)</td><td align="center" valign="middle" >1700</td><td align="center" valign="middle" >1460</td><td align="center" valign="middle" >−2.470</td><td align="center" valign="middle" >0.014</td></tr><tr><td align="center" valign="middle" >PLT恢复时间(d)</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >−0.754</td><td align="center" valign="middle" >0.451</td></tr><tr><td align="center" valign="middle" >PLT最低值(10<sup>9</sup>/L)</td><td align="center" valign="middle" >111</td><td align="center" valign="middle" >119.5</td><td align="center" valign="middle" >−1.571</td><td align="center" valign="middle" >0.129</td></tr><tr><td align="center" valign="middle" >胎龄小于34w</td><td align="center" valign="middle" >64 (51.6%)</td><td align="center" valign="middle" >52 (72.8%)</td><td align="center" valign="middle" >8.365</td><td align="center" valign="middle" >0.004</td></tr><tr><td align="center" valign="middle" >贫血</td><td align="center" valign="middle" >42 (33.9%)</td><td align="center" valign="middle" >46 (65.7%)</td><td align="center" valign="middle" >18.305</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >凝血异常</td><td align="center" valign="middle" >33 (26.6%)</td><td align="center" valign="middle" >12 (17.1%)</td><td align="center" valign="middle" >2.252</td><td align="center" valign="middle" >0.133</td></tr><tr><td align="center" valign="middle" >出血表现</td><td align="center" valign="middle" >49 (39.5%)</td><td align="center" valign="middle" >34 (48.6%)</td><td align="center" valign="middle" >1.499</td><td align="center" valign="middle" >0.221</td></tr><tr><td align="center" valign="middle" >轻度出血</td><td align="center" valign="middle" >37 (29.8%)</td><td align="center" valign="middle" >30 (42.9%)</td><td align="center" valign="middle" >3.354</td><td align="center" valign="middle" >0.067</td></tr><tr><td align="center" valign="middle" >重度出血</td><td align="center" valign="middle" >12 (9.7%)</td><td align="center" valign="middle" >4 (5.7%)</td><td align="center" valign="middle" >0.479</td><td align="center" valign="middle" >0.489</td></tr><tr><td align="center" valign="middle" >死亡或放弃</td><td align="center" valign="middle" >15 (12.1%)</td><td align="center" valign="middle" >6 (8.6%)</td><td align="center" valign="middle" >0.576</td><td align="center" valign="middle" >0.448</td></tr></tbody></table></table-wrap><p>表5. 早发型与晚发型血小板减少的临床分析比较</p><table-wrap id="table6" ><label><xref ref-type="table" rid="table6">Table 6</xref></label><caption><title> Clinical analysis of mild, moderate and severe thrombocytopenia in premature infant</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >轻度(n = 125)</th><th align="center" valign="middle" >中度(n = 53)</th><th align="center" valign="middle" >重度(n = 16)</th><th align="center" valign="middle" >X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >体重/(g)</td><td align="center" valign="middle" >1730</td><td align="center" valign="middle" >1490</td><td align="center" valign="middle" >1260</td><td align="center" valign="middle" >7.904</td><td align="center" valign="middle" >0.019</td></tr><tr><td align="center" valign="middle" >胎龄/(w)</td><td align="center" valign="middle" >33.14</td><td align="center" valign="middle" >32.43</td><td align="center" valign="middle" >31.22</td><td align="center" valign="middle" >2.396</td><td align="center" valign="middle" >0.302</td></tr><tr><td align="center" valign="middle" >PLT恢复时间(d)</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" >8</td><td align="center" valign="middle" >9</td><td align="center" valign="middle" >6.118</td><td align="center" valign="middle" >0.047</td></tr><tr><td align="center" valign="middle" >孕次</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >3</td><td align="center" valign="middle" >6.602</td><td align="center" valign="middle" >0.037</td></tr><tr><td align="center" valign="middle" >凝血异常</td><td align="center" valign="middle" >18 (14.4%)</td><td align="center" valign="middle" >18 (33.9%)</td><td align="center" valign="middle" >9 (56.3%)</td><td align="center" valign="middle" >18.689</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >输血或血制品</td><td align="center" valign="middle" >26 (20.8%)</td><td align="center" valign="middle" >28 (52.8%)</td><td align="center" valign="middle" >13 (81.3%)</td><td align="center" valign="middle" >33.721</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >输血小板</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >1 (1.8%)</td><td align="center" valign="middle" >9 (56.3%)</td><td align="center" valign="middle" >82.079</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >轻度出血</td><td align="center" valign="middle" >44 (35.2%)</td><td align="center" valign="middle" >18 (33.9%)</td><td align="center" valign="middle" >5 (31.3%)</td><td align="center" valign="middle" >0.109</td><td align="center" valign="middle" >0.947</td></tr><tr><td align="center" valign="middle" >重度出血</td><td align="center" valign="middle" >8 (6.4%)</td><td align="center" valign="middle" >1 (1.8%)</td><td align="center" valign="middle" >7 (43.8%)</td><td align="center" valign="middle" >30.048</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >无创呼吸机</td><td align="center" valign="middle" >54 (43.2%)</td><td align="center" valign="middle" >29 (54.7%)</td><td align="center" valign="middle" >12 (75.0%)</td><td align="center" valign="middle" >6.704</td><td align="center" valign="middle" >0.035</td></tr><tr><td align="center" valign="middle" >有创呼吸机</td><td align="center" valign="middle" >11 (8.8%)</td><td align="center" valign="middle" >7 (13.2%)</td><td align="center" valign="middle" >7 (43.8%)</td><td align="center" valign="middle" >15.441</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >死亡或放弃</td><td align="center" valign="middle" >7 (5.6%)</td><td align="center" valign="middle" >9 (17.0%)</td><td align="center" valign="middle" >5 (31.3%)</td><td align="center" valign="middle" >12.531</td><td align="center" valign="middle" >0.002</td></tr></tbody></table></table-wrap><p>表6. 早产儿轻度、中度、重度血小板减少临床分析比较</p></sec><sec id="s7_5"><title>3.5. 血小板输注情况以及临床结局分析</title><p>纳入研究的194例病例中，10例有血小板输注，其中6例治疗性应用(有严重出血)，另4例预防性应用(无严重出血)。将血小板输注组与无血小板输注组早产儿就胎龄、体重、出血情况、死亡或放弃治疗方面进行比较，发现有血小板输注组的重度出血、颅内出血比例均高于无血小板输注组，P值分别为0.000与0.011，见表7。</p><p>如表8所示，治疗性血小板输注组有3例死亡或放弃治疗，预防性血小板输注组均无重度出血及颅内出血，无死亡或放弃治疗。治疗性血小板输注组的胎龄、出生体重低于预防性血小板输注组，治疗性血小板输注组的重度出血明显高于预防性血小板输注组。</p><table-wrap id="table7" ><label><xref ref-type="table" rid="table7">Table 7</xref></label><caption><title> Clinical comparison between platelet infusion group and non-platelet infusion grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >血小板输注(n = 10)</th><th align="center" valign="middle" >无血小板输注(n = 184)</th><th align="center" valign="middle" >Z/X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >胎龄/(w)</td><td align="center" valign="middle" >31.215</td><td align="center" valign="middle" >32.86</td><td align="center" valign="middle" >−0.769</td><td align="center" valign="middle" >0.442</td></tr><tr><td align="center" valign="middle" >体重/(g)</td><td align="center" valign="middle" >1350</td><td align="center" valign="middle" >1600</td><td align="center" valign="middle" >−0.772</td><td align="center" valign="middle" >0.44</td></tr><tr><td align="center" valign="middle" >轻度出血</td><td align="center" valign="middle" >2 (20.0%)</td><td align="center" valign="middle" >65 (35.3%)</td><td align="center" valign="middle" >0.424</td><td align="center" valign="middle" >0.515</td></tr><tr><td align="center" valign="middle" >重度出血</td><td align="center" valign="middle" >6 (60.0%)</td><td align="center" valign="middle" >10 (5.4%)</td><td align="center" valign="middle" >30.455</td><td align="center" valign="middle" >0.000</td></tr><tr><td align="center" valign="middle" >颅内出血</td><td align="center" valign="middle" >3 (30.0%)</td><td align="center" valign="middle" >9 (4.9%)</td><td align="center" valign="middle" >6.432</td><td align="center" valign="middle" >0.011</td></tr><tr><td align="center" valign="middle" >死亡或放弃治疗</td><td align="center" valign="middle" >3 (30.0%)</td><td align="center" valign="middle" >18 (9.8%)</td><td align="center" valign="middle" >2.195</td><td align="center" valign="middle" >0.138</td></tr></tbody></table></table-wrap><p>表7. 血小板输注组与无血小板输注组早产儿临床比较</p><table-wrap id="table8" ><label><xref ref-type="table" rid="table8">Table 8</xref></label><caption><title> Clinical comparison between therapeutic platelet and prophylactic platelet transfusion in preterm infant</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >血小板输注治疗(n = 6)</th><th align="center" valign="middle" >血小板输注预防(n = 4)</th><th align="center" valign="middle" >Z/X<sup>2</sup></th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >胎龄/(w)</td><td align="center" valign="middle" >30</td><td align="center" valign="middle" >33.175</td><td align="center" valign="middle" >−2.132</td><td align="center" valign="middle" >0.033</td></tr><tr><td align="center" valign="middle" >体重/(g)</td><td align="center" valign="middle" >1055</td><td align="center" valign="middle" >2145</td><td align="center" valign="middle" >−2.138</td><td align="center" valign="middle" >0.032</td></tr><tr><td align="center" valign="middle" >轻度出血</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" >2 (50.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.133</td></tr><tr><td align="center" valign="middle" >重度出血</td><td align="center" valign="middle" >6 (100.0%)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.005</td></tr><tr><td align="center" valign="middle" >颅内出血</td><td align="center" valign="middle" >3 (50.0%)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.200</td></tr><tr><td align="center" valign="middle" >死亡或放弃治疗</td><td align="center" valign="middle" >3 (50.0%)</td><td align="center" valign="middle" >0 (0.0%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.200</td></tr></tbody></table></table-wrap><p>表8. 治疗性与预防性血小板输注早产儿临床比较</p></sec><sec id="s7_6"><title>3.6. 死亡或放弃治疗的原因分析</title><p>纳入研究的194例中有21例放弃治疗或者死亡，严重出血是死亡或放弃的首位原因，其次是先天发育畸形和NEC等。</p></sec></sec><sec id="s8"><title>4. 讨论</title><p>血小板减少是NICU中常见的血液系统疾病，尤其以早产儿常见。Beiner ME等研究入住新生儿监护室的早产儿，有31%至少有一次血小板计数小于150 &#215; 10<sup>9</sup>/L [<xref ref-type="bibr" rid="hanspub.41265-ref7">7</xref>]。受妊娠期不同因素影响以及自身各系统功能发育不成熟使得早产儿血小板减少与足月儿相比无论是病因还是临床结局都有很大不同，常常预示疾病的复杂性和严重性，甚至危及生命。需要及时识别其病因，并采取恰当处理。</p><p>血小板的生成和消耗受多种因素影响，某些早产儿可能同时存在多种引起血小板减少的高危因素。本研究将妊高症、SGA、宫内窘迫等纳入围产期因素，其中SGA、宫内窘迫主要引起血小板生成减少，妊高症既能抑制血小板生成，同时可以引起血小板破坏增加。从病因构成来看，无论分组如何，早产儿血小板减少的首位病因为围产期因素。早发型血小板减少组52.4%为围产期因素。胎龄 ≥ 34周组SGA、妊高症的比例高于胎龄 &lt; 34周组(P值分别为0.006、0.042)。Beiner ME等报道 [<xref ref-type="bibr" rid="hanspub.41265-ref7">7</xref>] 宫内生长受限与早产儿血小板减少症显著相关。SGA的发生机制比较复杂，约40%的患儿病因尚不明确，但是目前认为SGA的患儿存在慢性的宫内缺氧。胎儿慢性缺氧可诱导红细胞生成增加，进而抑制骨髓中血小板的生成 [<xref ref-type="bibr" rid="hanspub.41265-ref1">1</xref>]，妊娠期越长，胎儿宫内缺氧情况约严重，越容易引起血小板减低。妊高症除了导致宫内慢性缺氧，同时可引起全身小血管痉挛，内皮细胞损伤导致血小板黏附聚集且消耗增加 [<xref ref-type="bibr" rid="hanspub.41265-ref6">6</xref>]，妊高症一般发生在妊娠20周以后，病理改变的发生早于临床表现 [<xref ref-type="bibr" rid="hanspub.41265-ref8">8</xref>]，妊娠后期血管内皮细胞损伤程度重，引起血小板消耗增多。早发型血小板减少组的首位病因为围产期因素，高于晚发型血小板减少组(P = 0.001)。既往报道早发型血小板减少症最常见的原因与胎儿慢性缺氧有关，慢性缺氧导致的血小板减少为轻度或中度，并且是自限性的，大多数病例在10天内恢复 [<xref ref-type="bibr" rid="hanspub.41265-ref9">9</xref>]，本研究发现有6例围产期因素导致的重度血小板减少，可能与严重围产期缺氧有关，轻度、中度、重度减少组患儿血小板平均恢复时间分别为6天、8天、9天，均在10天内恢复。</p><p>胎龄 &lt; 34周组的第二位病因为NRDS，明显高于≥34周组(P = 0.001)。这与胎龄小，肺部发育不成熟使其发病率增加有关，同时早产儿NRDS继发肺损伤引起的炎症反应导致血小板激活并聚集在肺部，可使血小板、巨核细胞消耗和破坏增加，循环血中的血小板数量减少。Brus等的研究 [<xref ref-type="bibr" rid="hanspub.41265-ref10">10</xref>] 发现早产儿NRDS易引起血小板减少，而且血小板减少的程度与NRDS的严重性成正比。他们同时指出NRDS肺损伤时，引起血小板激活和聚集，血小板消耗增加。Emma Lefrancais等 [<xref ref-type="bibr" rid="hanspub.41265-ref11">11</xref>] 通过观察鼠的肺部微小血管中细胞行为发现肺是巨核细胞循环和血小板生成重要场所。</p><p>Murray NA等 [<xref ref-type="bibr" rid="hanspub.41265-ref12">12</xref>] 研究发现晚发型血小板减少症常由败血症或NEC引起，本研究发现晚发型血小板减少组首位病因仍然是围产期因素(28.6%)，考虑在生后3天，围产期因素导致的血管内皮细胞损伤仍不能恢复，致使血小板破坏仍然存在，最终引起血小板进行性下降，也可能与筛查时间有关。败血症和NEC是晚发型血小板减少的重要原因(分别占17.1%和11.4%)。晚发型血小板减少组胎龄、体重明显低于早发型血小板减少，NEC、败血症明显高于早发型血小板减少组(P &lt; 0.001)，说明早产儿免疫力低下，从母体获得的抗体慢慢消耗，后期更容易发生感染及NEC等情况，引起血小板减少。NEC是多种病因导致的肠道坏死，全身炎症反应，是早产儿住院后期肠道的严重并发症，包括产前及生后因素，例如胎盘功能不全、早产、胎膜早破、绒毛膜羊膜炎、肠道缺血、细菌定植改变，感染、细菌过度生长和输注红细胞等有关 [<xref ref-type="bibr" rid="hanspub.41265-ref13">13</xref>]。其中炎症介质是引起NEC重要因素，炎症会影响血管内皮细胞功能，导致血小板及巨核细胞消耗和破坏增加，从而引起血小板减少 [<xref ref-type="bibr" rid="hanspub.41265-ref14">14</xref>]。既往有报道晚发血小板减少的最常见和临床重要原因是脓毒症和NEC [<xref ref-type="bibr" rid="hanspub.41265-ref15">15</xref>]。Murray NA等研究 [<xref ref-type="bibr" rid="hanspub.41265-ref12">12</xref>] 发现晚发型血小板减少症常由败血症或坏死小肠结肠炎引起，而且这些临床病例中血小板通常会非常迅速降低，血小板计数 &lt; 30 &#215; 10<sup>9</sup>/L，可能需要较长时间恢复。本研究中重度血小板减少组败血症、NEC比例高于其它两组。NEC导致的血小板减少程度严重，恢复时间最长，临床需要高度重视。</p><p>重度血小板减少定义为血小板 &lt; 50 &#215; 10<sup>9</sup>/L。研究结果提示重度血小板减少组患儿，出血机率增加，且出血程度重。丘惠娴等研究 [<xref ref-type="bibr" rid="hanspub.41265-ref16">16</xref>] 脑室周围–脑室内出血(periventricular-intraventricular hemorrhage, PVH-IVH)的早产儿血小板计数显著低于无PVH-IVH者，且病情愈重，下降愈明显，这与本研究结果一致。重度血小板减少组出生体重明显低于轻–中度血小板减少组(P = 0.019)，临床情况严重复杂，合并凝血异常、重要脏器出血比例明显增加(P值均为0.000)，需要输血或血制品及呼吸支持的比例明显增加，死亡与放弃治疗的几率提高(P = 0.002)。提示重度血小板减少往往病情较重，病因复杂，合并症多，应重点进行综合评估，及时干预，以防严重出血危及生命及预后。</p><p>输注血小板是为了预防出血导致的严重并发症，目前血小板输注阈值尚不统一。少数机构主张只要有活动性出血，无论血小板减少程度，均给予血小板输注治疗 [<xref ref-type="bibr" rid="hanspub.41265-ref1">1</xref>]。有些研究认为当血小板 &lt; 20~30 &#215; 10<sup>9</sup>/L或血小板 &lt; 50 &#215; 10<sup>9</sup>/L伴出血症状时，可以考虑输注血小板 [<xref ref-type="bibr" rid="hanspub.41265-ref17">17</xref>]。近年来有研究发现，采用血小板计数25 &#215; 10<sup>9</sup>/L这一输注阈值比血小板计数50 &#215; 10<sup>9</sup>/L，其死亡率和严重出血发生率显著降低 [<xref ref-type="bibr" rid="hanspub.41265-ref18">18</xref>]。本研究共有10例患儿输注了血小板，其中4例为预防性输注，平均阈值31 &#215; 10<sup>9</sup>/L，6例为治疗性输注，平均阈值25 &#215; 10<sup>9</sup>/L。血小板输注组没有减少严重出血，而且其出血表现、重度出血、颅内出血高于无血小板输注组。主要因为治疗性血小板输注所占比例较高，输注组患儿相对来说病情较危重。血小板输注组与无血小板输注组死亡或放弃治疗方面无统计学差异，治疗性血小板输注与预防血小板输注两组间死亡或放弃治疗无显著差异。目前国内尚无针对新生儿血小板输注阈值的指南，本研究血小板输注组样本量比较少，必要时可增大样本量，进一步研究血小板输注阈值对早产儿临床结局的影响。</p></sec><sec id="s9"><title>5. 结论</title><p>综上，导致早产儿血小板减少的病因以围产期因素最为常见，需要加强围产期保健，积极治疗妊娠合并症，提高早产儿生存质量。败血症、NEC是晚发型血小板减少的重要原因，血小板减少程度重，临床症状严重复杂，重度出血比例高，预后不良。血小板输注并没有减少严重出血的发生，有必要综合临床评估决定血小板输注阈值。</p></sec><sec id="s10"><title>文章引用</title><p>袁 芮,李向红,郝荣真,杨丽娟. 早产儿血小板减少症的临床特征及结局分析Clinical Characteristics and Outcome Analysis of Premature Infants with Thrombocytopenia[J]. 临床医学进展, 2021, 11(03): 1284-1293. https://doi.org/10.12677/ACM.2021.113184</p></sec><sec id="s11"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.41265-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Gunnink, S.F., et al. (2014) Neonatal Thrombocytopenia: Etiology, Management and Outcome. Expert Review of Hematology, 7, 387-395. &lt;br&gt;https://doi.org/10.1586/17474086.2014.902301</mixed-citation></ref><ref id="hanspub.41265-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Del, V.A., et al. (2012) A Consistent Approach to Platelet Transfusion in the NICU. Journal of Maternal-Fetal and Neonatal Medicine, 25, 93-96. &lt;br&gt;https://doi.org/10.3109/14767058.2012.716985</mixed-citation></ref><ref id="hanspub.41265-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Sola-Visner, M., Saxonhouse, M.A. and Brown, R.E. (2008) Neonatal Thrombocytopenia: What We Do and Don’t Know. Early Human Development, 84, 499-506. &lt;br&gt;https://doi.org/10.1016/j.earlhumdev.2008.06.004</mixed-citation></ref><ref id="hanspub.41265-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Wiedmeier, S.E., et al. (2009) Platelet Reference Ranges for Neonates, Defined Using Data from over 47,000 Patients in a Multihospital Healthcare System. Journal of Perinatology, 29, 130-136. &lt;br&gt;https://doi.org/10.1038/jp.2008.141</mixed-citation></ref><ref id="hanspub.41265-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Sainio, S., et al. (2000) Thrombocytopenia in Term Infants: A Population-Based Study. Obstetrics &amp; Gynecology, 95, 441-446. &lt;br&gt;https://doi.org/10.1097/00006250-200003000-00025</mixed-citation></ref><ref id="hanspub.41265-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">黄琼辉, 刘捷, 曾超美. 新生儿血小板减少症诊断与治疗进展[J]. 中华临床医师杂志(电子版), 2017, 11(14): 2046-2049.</mixed-citation></ref><ref id="hanspub.41265-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Beiner, M.E., et al. (2003) Risk Factors for Neonatal Thrombocytopenia in Preterm Infants. American Journal of Perinatology, 20, 49-54. &lt;br&gt;https://doi.org/10.1055/s-2003-37948</mixed-citation></ref><ref id="hanspub.41265-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">万淑梅, 等. 妊娠期高血压疾病严重并发症的发生规律及其对母儿的影响[J]. 中华妇产科杂志, 2007, 42(8): 510-514.</mixed-citation></ref><ref id="hanspub.41265-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Murray, N.A. and Roberts, I.A. (1996) Circulating Megakaryocytes and Their Progenitors in Early Thrombocytopenia in Preterm Neonates. Pediatric Research, 40, 112-119. &lt;br&gt;https://doi.org/10.1203/00006450-199607000-00020</mixed-citation></ref><ref id="hanspub.41265-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Brus, F., et al. (1997) Number and Activation of Circulating Polymorphonuclear Leukocytes and Platelets Are Associated with Neonatal Respiratory Distress Syndrome Severity. Pediatrics, 99, 672-680.  
&lt;br&gt;https://doi.org/10.1542/peds.99.5.672</mixed-citation></ref><ref id="hanspub.41265-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lefrancais, E., et al. (2017) The Lung Is a Site of Platelet Biogenesis and a Reservoir for Haematopoietic Progenitors. Nature, 544, 105-109. &lt;br&gt;https://doi.org/10.1038/nature21706</mixed-citation></ref><ref id="hanspub.41265-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Murray, N.A., et al. (2002) Platelet Transfusion in the Management of Severe Thrombocytopenia in Neonatal Intensive Care Unit Patients. Transfusion Medicine, 12, 35-41. &lt;br&gt;https://doi.org/10.1046/j.1365-3148.2002.00343.x</mixed-citation></ref><ref id="hanspub.41265-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Neu, J. and Walker, W.A. (2011) Necrotizing Enterocolitis. The New England Journal of Medicine, 364, 255-264.  
&lt;br&gt;https://doi.org/10.1056/NEJMra1005408</mixed-citation></ref><ref id="hanspub.41265-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">马英, 等. 新生儿血小板减少症102例临床分析[J]. 临床医学研究与实践, 2019, 4(8): 80-81+85.</mixed-citation></ref><ref id="hanspub.41265-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Resch, E., et al. (2018) Neonatal Thrombocytopenia—Causes and Outcomes Following Platelet Transfusions. European Journal of Pediatrics, 177, 1045-1052. &lt;br&gt;https://doi.org/10.1007/s00431-018-3153-7</mixed-citation></ref><ref id="hanspub.41265-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">丘惠娴, 等. 脑室周围-脑室内出血早产儿血小板参数的变化及临床意义[J]. 中国实验诊断学, 2010, 14(5): 666-668.</mixed-citation></ref><ref id="hanspub.41265-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Cremer, M., et al. (2011) Platelet Transfusions in Neonates: Practices in the United States Vary Significantly from Those in Austria, Germany, and Switzerland. Transfusion, 51, 2634-2641.  
&lt;br&gt;https://doi.org/10.1111/j.1537-2995.2011.03208.x</mixed-citation></ref><ref id="hanspub.41265-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Curley, A., et al. (2019) Randomized Trial of Platelet-Transfusion Thresholds in Neonates. The New England Journal of Medicine, 380, 242-251. &lt;br&gt;https://doi.org/10.1056/NEJMoa1807320</mixed-citation></ref></ref-list></back></article>